Prediction of imminent preeclampsia at 35-37 weeks gestation.

Affiliation

Harris Birthright Research Centre for Fetal Medicine, King's College, London, UK. Electronic address: [Email]

Abstract

In the weeks preceding the clinical onset of preeclampsia, the maternal serum level of the angiogenic placental growth factor is decreased and that of the antiangiogenic factor soluble fms-like tyrosine kinase-1 is increased. Women presenting at specialist clinics with signs or symptoms of hypertensive disorders have been stratified according to concentrations of placental growth factor or the ratio of concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor to determine clinical management for the subsequent 1-4 weeks. An alternative approach for the prediction of preeclampsia is use of the competing risks model, a Bayes' theorem based method, to derive patient-specific risk for preeclampsia by various combinations of maternal characteristics and medical history with multiples of the median values of biomarkers.

Keywords

biomarker,competing risks model,mean arterial pressure,placental growth factor,preeclampsia,screening,soluble fms-like tyrosine kinase-1,third trimester,

OUR Recent Articles